%0 Journal Article
%T Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.
%A Li Z
%A Zhao H
%A Hu H
%A Shang H
%A Ren Y
%A Qiu W
%A Su H
%A Lyu H
%A Chen X
%J Chin J Cancer Res
%V 36
%N 3
%D 2024 Jun 30
%M 38988489
%F 4.026
%R 10.21147/j.issn.1000-9604.2024.03.07
%X Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2 (HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.